The phase 2 LEGION‑100 study is evaluating an investigational treatment called SYNC‑T Therapy SV‑102 for men with mCRPC. SYNC‑T SV-102 therapy is an outpatient procedure that involves placing a needle-like device into the tumor using image guidance (CT or ultrasound), followed by infusion directly into the tumor of the study drug (SV-102) to help the immune system fight cancer throughout the body and at the treated tumor site. The procedure involves 2 steps:

A needle-like device is inserted into the tumor to freeze a portion of the tumor cells and break them to release specific proteins that help your immune system recognize the cancer.
Immediately after breaking open the tumor cells, the same needle-like device is used to infuse the study drug, SV-102, directly into the same tumor area.

Together, the combination of breaking open tumor cells and then infusing SV-102, is designed to activate your immune system and educate it to recognize and attack cancer throughout your entire body.

Join Dr. Gerald L. Andriole, Jr., who is the Chief Medical Officer of Urology at Syncromune, as he explains:

• LEGION-100 SYNC-T Therapy
• Two treatment procedure steps
• Early findings and safety